DK0572537T3 - Cytokinnhibitorer - Google Patents

Cytokinnhibitorer

Info

Publication number
DK0572537T3
DK0572537T3 DK92907362T DK92907362T DK0572537T3 DK 0572537 T3 DK0572537 T3 DK 0572537T3 DK 92907362 T DK92907362 T DK 92907362T DK 92907362 T DK92907362 T DK 92907362T DK 0572537 T3 DK0572537 T3 DK 0572537T3
Authority
DK
Denmark
Prior art keywords
production
inhibiting
cytokine inhibitors
mammal
interleukin
Prior art date
Application number
DK92907362T
Other languages
Danish (da)
English (en)
Inventor
Alison Mary Badger
Wanda Bernadette High
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of DK0572537T3 publication Critical patent/DK0572537T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK92907362T 1991-02-19 1992-02-18 Cytokinnhibitorer DK0572537T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65757891A 1991-02-19 1991-02-19
PCT/US1992/001283 WO1992014462A1 (fr) 1991-02-19 1992-02-18 Inhibiteurs de cytokines

Publications (1)

Publication Number Publication Date
DK0572537T3 true DK0572537T3 (da) 2000-03-27

Family

ID=24637788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907362T DK0572537T3 (da) 1991-02-19 1992-02-18 Cytokinnhibitorer

Country Status (14)

Country Link
US (2) US5602166A (fr)
EP (1) EP0572537B1 (fr)
JP (1) JP3162071B2 (fr)
KR (1) KR930702975A (fr)
AT (1) ATE186641T1 (fr)
AU (1) AU657745B2 (fr)
CA (1) CA2104214C (fr)
DE (1) DE69230314T2 (fr)
DK (1) DK0572537T3 (fr)
ES (1) ES2138595T3 (fr)
GR (1) GR3032612T3 (fr)
IE (1) IE920508A1 (fr)
WO (1) WO1992014462A1 (fr)
ZA (1) ZA921120B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201804D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9201803D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9315351D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315340D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315306D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9414902D0 (en) * 1994-07-23 1994-09-14 Smithkline Beecham Corp Methods
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
JP3195364B2 (ja) * 1995-07-13 2001-08-06 アノーメッド インコーポレイティド Ｎ，ｎ−ジメチル−８，８−ジプロピル−２−アザスピロ〔４．５〕デカン−２−プロパンアミン・ジマレエート
CN1219129A (zh) * 1996-05-17 1999-06-09 安诺梅德公司 取代的氮杂螺烷在治疗哮喘中的用途
GB2309167A (en) * 1997-05-10 1997-07-23 Anormed Inc The use of azaspiranes in the treatment of Alzheimer's disease
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
CO5190696A1 (es) * 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
WO2002080970A1 (fr) * 2001-03-23 2002-10-17 Regents Of The University Of California Methode pour inhiber la calcification de la matrice du cartilage articulaire
US7674838B2 (en) * 2002-04-05 2010-03-09 Henkel Corporation Curable foam elastomeric compositions
CA2518357A1 (fr) * 2003-03-10 2004-09-23 Callisto Pharmaceuticals, Inc. Methode de traitement du cancer a l'aide de compositions a base d'azaspirane
WO2010091381A2 (fr) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Stratégie d'administration intermittente pour le traitement de la polyarthrite rhumatoïde

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106552A (en) 1960-07-19 1963-10-08 Geschickter Fund Med Res Nu-substituted azaspiranes and azaspirane-diones and processes for their preparation
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
HU215434B (hu) 1988-05-27 1999-04-28 Synergen Inc. Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására

Also Published As

Publication number Publication date
WO1992014462A1 (fr) 1992-09-03
ZA921120B (en) 1993-01-27
JPH06505483A (ja) 1994-06-23
US5900430A (en) 1999-05-04
ES2138595T3 (es) 2000-01-16
KR930702975A (ko) 1993-11-29
GR3032612T3 (en) 2000-05-31
EP0572537A4 (fr) 1993-10-14
AU657745B2 (en) 1995-03-23
IE920508A1 (en) 1992-08-26
DE69230314T2 (de) 2000-02-24
EP0572537A1 (fr) 1993-12-08
EP0572537B1 (fr) 1999-11-17
JP3162071B2 (ja) 2001-04-25
AU1463392A (en) 1992-09-15
DE69230314D1 (de) 1999-12-23
ATE186641T1 (de) 1999-12-15
US5602166A (en) 1997-02-11
CA2104214A1 (fr) 1992-08-20
CA2104214C (fr) 2004-04-27

Similar Documents

Publication Publication Date Title
DK0572537T3 (da) Cytokinnhibitorer
NO942618L (no) Imidazolderivater og deres anvendelse som cytokin-inhibitorer
IL135068A0 (en) Stimulation of hematopoietic cells in vitro
ES2192227T3 (es) Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones.
EP0715619A4 (fr) Inhibiteurs de la secretion de facteur alpha de necrose tumorale
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
DK0527879T3 (da) Synergistiske terapeutiske præparater og fremgangsmåder.
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
NO905090L (no) Interleukin-1-inhibitorer og fremgangsmaate til deres fremstilling.
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
MX9205875A (es) Compuestos.
ATE346041T1 (de) N-hydroxyformamid-derivate
GB8907305D0 (en) High slew rate linear amplifier
DE69535961D1 (de) T-zellaktivierung
KR950703064A (ko) 세포증식의 저해물질, 그의 제조방법 및 이용방법
ES2120962T3 (es) Composicion antivirica.
NO890046L (no) Disubstituerte pyridiner.
IT8420506V0 (it) Dispositivo di regolazione e di posizionamento per una poltrona.
ATE59553T1 (de) Polyhydroxybenzoesaeure-abkoemmlinge.
ITTO910787A0 (it) Amplificatore di potenza, in particolare di tipo audio
ATE76579T1 (de) Interferon-zusammensetzungen.
FI962264A0 (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
ES2078501T3 (es) Metodo para el tratamiento de la trombocitopenia y composiciones farmaceuticas utiles para el mismo.